Sun Yadong, Duan Fujiao, Liu Weigang, Peng Zhen, Dai Liping, Feng Yajing, Yang Zhenxing, Shang Jia, Wang Kaijuan
Department of Breast and Medical Research Office, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
College of Public Health, Zhengzhou University, Zhengzhou, China.
Front Oncol. 2018 Jul 16;8:252. doi: 10.3389/fonc.2018.00252. eCollection 2018.
Numerous studies have demonstrated the presence of microRNA-124 abnormalities involving gene expression, methylation, and single nucleotide polymorphism (SNP) in multiple and diverse cancers, but the prognostic value of these abnormalities in cancer remains inconclusive.
The aim of this study is to determine the prognostic value of miR-124 in cancer.
We scrutinized the electronic databases and estimate the association between miR-124 expression, methylation and single nucleotide polymorphisms (SNPs), and prognosis in cancers. The pooled hazard ratios with 95% confidence intervals (CIs) for overall survival (OS), and disease-free survival/recurrence-free survival (RFS)/progression-free survival (PFS) were calculated to estimate the effects of miR-124 expression, methylation, and SNPs on cancer prognosis. The Quality in Prognosis Studies and Newcastle-Ottawa Scale were utilized to assess the quality of included studies.
A total of 20 studies involving 3,574 participants were analyzed in evidence synthesis. Our findings showed that the low expression of miR-124 was significantly associated with poor OS (HR = 2.37, 95% CI: 1.91-2.94, = 0.00; HR = 3.10, 95% CI: 2.04-4.70, = 0.00) and PFS/RFS (HR = 2.21, 95% CI: 1.50-3.26, = 0.00; HR = 2.12, 95% CI: 1.20-3.74, = 0.00). The hyper-methylation of miR-124 was associated with poor OS (HR = 2.09, 95% CI: 1.48-2.95, = 0.00) and PFS (HR = 3.70, 95% CI: 1.72-7.97, = 0.00) (Table 3). The patients carrying with Allele C of miR-124 rs5315649 had a worse OS (HR = 1.50, 95% CI: 1.09-2.07, = 0.00) and PFS (HR = 1.67, 95% CI: 1.20-2.33, = 0.00) than the carriers with Allele G.
The low expression and hyper-methylation of miR-124 was strongly associated with poor prognosis, and genetic variations of miR-124 rs531564 affected prognosis in cancer patients.
大量研究已证实在多种不同癌症中存在涉及基因表达、甲基化和单核苷酸多态性（SNP）的微小RNA - 124异常，但这些异常在癌症中的预后价值仍无定论。
本研究旨在确定miR - 124在癌症中的预后价值。
我们仔细查阅了电子数据库，并评估了miR - 124表达、甲基化和单核苷酸多态性（SNP）与癌症预后之间的关联。计算总生存（OS）、无病生存/无复发生存（RFS）/无进展生存（PFS）的合并风险比及95%置信区间（CI），以评估miR - 124表达、甲基化和SNP对癌症预后的影响。采用预后研究质量评估量表和纽卡斯尔 - 渥太华量表来评估纳入研究的质量。
证据综合分析共纳入20项研究，涉及3574名参与者。我们的研究结果表明，miR - 124低表达与较差的总生存（HR = 2.37，95% CI：1.91 - 2.94，P = 0.00；HR = 3.10，95% CI：2.04 - 4.70，P = 0.00）和无进展生存/无复发生存（HR = 2.21，95% CI：1.50 - 3.26，P = 0.00；HR = 2.12，95% CI：1.20 - 3.74，P = 0.00）显著相关。miR - 124高甲基化与较差的总生存（HR = 2.09，95% CI：1.48 - 2.95，P = 0.00）和无进展生存（HR = 3.70，95% CI：1.72 - 7.97，P = 0.00）相关（表3）。携带miR - 124 rs5315649等位基因C的患者总生存（HR = 1.50，95% CI：1.09 - 2.07，P = 0.00）和无进展生存（HR = 1.67，95% CI：1.20 - 2.33，P = 0.00）比携带等位基因G的患者差。
miR - 124的低表达和高甲基化与不良预后密切相关，miR - 124 rs531564的基因变异影响癌症患者的预后。
